公开(公告)号：US20210105980A1

公开(公告)日：2021-04-15

申请号：US17050199

申请日：2019-04-25

Applicant: Hoffmann-La Roche Inc. ,  HOFFMANN-LA ROCHE INC.

Inventor： Przemek IDZIASZEK ,  Antoni OPOLSKI ,  Jacek ZIEMSKI ,  Bartosz BINIAS

IPC: A01K29/00 ,  A01K11/00

Abstract: A method of tracking an animal (4) in a population of animals (4) comprises: applying a visual identifier (41) to the animal (4); associating reference identifier data of the visual identifier (41) to animal data of the animal (4); capturing a digital image of the visual identifier (41) applied to the animal (4); recognizing the visual identifier (41) by digitally processing the captured digital image; and identifying the animal (4) upon recognition of the visual identifier (41).

公开(公告)号：US20210003559A1

公开(公告)日：2021-01-07

申请号：US16912391

申请日：2020-06-25

Applicant: Hoffmann-La Roche Inc. ,  F. Hoffmann-La Roche AG ,  Emulate, Inc.

Inventor： Cristina Bertinetti-Lapatki ,  Lauriane Cabon ,  Adrian B. Roth ,  Annie Moisan ,  Nikolche Gjorevski ,  Jordan S. Kerns ,  Geraldine A. Hamilton ,  Catherine Karalis ,  Heather Grant ,  Riccardo Barrile ,  Debora Barreiros Petropolis ,  Chaitra Belgur

IPC: G01N33/50

Abstract: Disclosed herein is a method for assessing a compound interacting with a target on polarized epithelial cells. The method comprising the steps of providing an organ chip comprising a main channel and polarized epithelial cells, wherein the main channel is divided into an apical channel and a basal channel separated by the polarized epithelial cells, wherein the apical side of the polarized epithelial cells is directed towards the apical channel and the basolateral side of the polarized epithelial cells is directed towards the basal channel. Determining the localization and optionally the expression level of the target on the polarized epithelial cells. Administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the basal channel, when the target is localized on the basolateral side of the epithelial cells or administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the apical channel, when the target is localized on the apical side of the epithelial cells. Measuring a parameter of the administration of the compound and the peripheral blood mononuclear cells.

公开(公告)号：US20200071411A1

公开(公告)日：2020-03-05

申请号：US16684258

申请日：2019-11-14

Applicant: Hoffmann-La Roche Inc. ,  Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Peter BRUENKER ,  Christina CLAUS ,  Claudia FERRARA KOLLER ,  Sandra GRAU-RICHARDS ,  Ralf HOSSE ,  Christian KLEIN ,  Viktor LEVITSKI ,  Pablo UMANA

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/40

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20150368642A1

公开(公告)日：2015-12-24

申请号：US14764658

申请日：2014-01-30

Applicant: HOFFMANN-LA ROCHE INC. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Nanna ALBÆK ,  Henrik Frydenlund HANSEN ,  Susanne KAMMLER ,  Jacob RAVN ,  Henrik ØRUM ,  Mark TURNER ,  Monika KRAMPERT ,  Philipp HADWIGER ,  Søren OTTOSEN ,  Morten LINDOW

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/48

CPC classification number: C12N15/113 ,  A61K31/712 ,  A61K31/713 ,  A61K47/55 ,  A61K47/64 ,  C12N15/1131 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2320/30 ,  C12N2330/30

Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.

Abstract translation: 本发明提供具有显着增强的效力，延长的治疗指数和降低的毒性的LNA治疗性寡核苷酸碳水化合物缀合物。

公开(公告)号：US09464098B2

公开(公告)日：2016-10-11

申请号：US14646782

申请日：2013-11-29

Applicant: Hoffmann-La Roche Inc. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Stephen M. Lynch ,  Werner Neidhart ,  Jean-Marc Plancher ,  Tanja Schulz-Gasch

IPC: A61K31/4192 ,  C07F5/02

CPC classification number: C07F5/025

Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.

公开(公告)号：US10060917B2

公开(公告)日：2018-08-28

申请号：US14904039

申请日：2014-07-11

Applicant: F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

Inventor： Christof Fattinger

IPC: G01N33/551 ,  G01N33/543 ,  G01N21/77

CPC classification number: G01N33/54386 ,  G01N21/7743 ,  G01N33/54373

Abstract: A device (1) for use in the detection of binding affinities comprises a planar waveguide (2) arranged on a substrate (22). The waveguide (2) has an outer surface (21) and a plurality of incoupling lines (31) for coupling a beam of coherent light into the waveguide (2) such that a parallel beam of coherent light (62) propagates along the waveguide (2). The incoupling lines (31) are curved and have an increasing distance between adjacent incoupling lines (31). A divergent beam of coherent light (61) of a predetermined wavelength is coupled into the waveguide (2) such that it propagates along the waveguide (2). A plurality of binding sites (51) is attached to the outer surface (21) along at least one further plurality of diffraction lines arranged in an outcoupling section of the waveguide (2). These diffraction lines comprise a plurality of curved outcoupling lines (41) having a decreasing distance between adjacent outcoupling lines. They decouple a diffracted portion of coherent light from the planar waveguide (2), and the decoupled portion of coherent light (63) converges into a predetermined second focal location (631).

公开(公告)号：US20160161477A1

公开(公告)日：2016-06-09

申请号：US14904039

申请日：2014-07-11

Applicant: F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

Inventor： Christof Fattinger

IPC: G01N33/543

CPC classification number: G01N33/54386 ,  G01N21/7743 ,  G01N33/54373

Abstract: A device (1) for use in the detection of binding affinities comprises a planar waveguide (2) arranged on a substrate (22). The waveguide (2) has an outer surface (21) and a plurality of incoupling lines (31) for coupling a beam of coherent light into the waveguide (2) such that a parallel beam of coherent light (62) propagates along the waveguide (2). The incoupling lines (31) are curved and have an increasing distance between adjacent incoupling lines (31). A divergent beam of coherent light (61) of a predetermined wavelength is coupled into the waveguide (2) such that it propagates along the waveguide (2). A plurality of binding sites (51) is attached to the outer surface (21) along at least one further plurality of diffraction lines arranged in an outcoupling section of the waveguide (2). These diffraction lines comprise a plurality of curved outcoupling lines (41) having a decreasing distance between adjacent outcoupling lines. They decouple a diffracted portion of coherent light from the planar waveguide (2), and the decoupled portion of coherent light (63) converges into a predetermined second focal location (631).

Abstract translation: 用于检测结合亲和力的装置（1）包括布置在基底（22）上的平面波导（2）。 波导（2）具有外表面（21）和多个入射线（31），用于将相干光束耦合到波导（2）中，使得平行的相干光束（62）沿着波导（ 2）。 连接线（31）是弯曲的并且在相邻的连接线（31）之间具有增加的距离。 将预定波长的相干光（61）的发散光束耦合到波导（2）中，使得其沿着波导（2）传播。 沿着布置在波导管（2）的外耦合部分中的至少一个其它多个衍射线，多个结合位置（51）附接到外表面（21）。 这些衍射线包括多个弯曲的输出耦合线（41），其相邻的输出耦合线之间的距离减小。 它们将来自平面波导（2）的相干光的衍射部分分离，并且相干光（63）的解耦部分会聚到预定的第二焦点位置（631）。

公开(公告)号：US20250152582A1

公开(公告)日：2025-05-15

申请号：US19030370

申请日：2025-01-17

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/00 ,  A61K39/395

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US12300384B2

公开(公告)日：2025-05-13

申请号：US17502911

申请日：2021-10-15

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Andreas Maunz ,  Ian Lloyd Jones

IPC: G06K9/00 ,  G06F18/214 ,  G06T7/00 ,  G16H10/20 ,  G16H50/20

Abstract: Embodiments described herein provide methods and systems for predicting a subject response to a therapeutic. The methods and systems generally operate by using a machine learning (ML) component trained using time-series responses and image features to generate time-series responses of a subject to a therapeutic that has been administered to the subject.

公开(公告)号：US12291561B2

公开(公告)日：2025-05-06

申请号：US18312339

申请日：2023-05-04

Applicant: Hoffmann-La Roche Inc.

Inventor： Kay-Gunnar Stubenrauch ,  Ekkehard Moessner ,  Christian Klein ,  Diana Darowski

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  A61K38/00

Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.